Acadia pharmaceuticals appoints doug williamson, m.d., as executive vice president, head of research and development

San diego--( business wire )--acadia pharmaceuticals inc. (nasdaq: acad) announced today the appointment of dr. doug williamson as executive vice president, head of research and development (r&d). dr. williamson will lead research and development at acadia and will serve as a member of the company's executive management committee, reporting to steve davis, chief executive officer of acadia. dr. williamson will succeed dr. srdjan stankovic, whose planned retirement was announced last year.
ACAD Ratings Summary
ACAD Quant Ranking